Cost of Care for Juvenile Idiopathic Arthritis
1 other identifier
observational
165
1 country
3
Brief Summary
This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine methods by which to reduce the economic impact while improving outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2012
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2011
CompletedFirst Posted
Study publicly available on registry
November 10, 2011
CompletedStudy Start
First participant enrolled
January 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedJanuary 17, 2018
January 1, 2018
2.9 years
November 3, 2011
January 12, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Direct and indirect costs
Patient's history will be reviewed for the prior 6 months to enrollment for expenses incurred related to JIA and it's treatment. This will be done through chart review and questionnaires completed by the patient/parent.
6 months prior to enrollment
Secondary Outcomes (1)
Health related quality of life questionnaires
Day 1
Eligibility Criteria
Children, adolescents, and young adults with JIA within Cleveland Clinic Health System and at several other participating study sites.
You may qualify if:
- Subject has been diagnosed with JIA by a pediatric rheumatologist according to published criteria.
- Person providing consent must be able to read English.
- Subject (and/or parent/legal guardian) is able to provide informed consent and willing to comply with study procedures.
You may not qualify if:
- Subject/ legal guardian is unwilling to provide consent, cannot read English, or does not meet published criteria for JIA.
- Coexisting rheumatologic disorder
- Diagnosis of fibromyalgia
- Participation in a drug trial in the past 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Children's Hospital & Medical Center
Omaha, Nebraska, 68114, United States
The Cleveland Clinic
Cleveland, Ohio, 44195, United States
Dell Childrens Medical Center of Central Texas
Austin, Texas, 78723, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrew Zeft, MD
Cleveland Clinic Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Center for Pediatric Rheumatology
Study Record Dates
First Submitted
November 3, 2011
First Posted
November 10, 2011
Study Start
January 1, 2012
Primary Completion
December 1, 2014
Study Completion
March 1, 2017
Last Updated
January 17, 2018
Record last verified: 2018-01